Curated News
By: NewsRamp Editorial Staff
August 10, 2026
Quantum BioPharma Gets FDA Nod for Lucid-MS Phase 2 MS Trial
TLDR
- Quantum BioPharma's FDA approval for Lucid-MS Phase 2 gives it a first-mover edge in neuroprotective MS treatments.
- Lucid-MS inhibits PAD2 enzyme to prevent demyelination; Phase 2 trial will assess safety and efficacy in MS patients.
- This therapy could halt MS progression by protecting myelin, offering hope for improved quality of life.
- Lucid-MS uniquely targets PAD2, reversing myelin damage, unlike traditional MS drugs that only modulate immunity.
Impact - Why it Matters
This FDA clearance is a pivotal moment for Quantum BioPharma and the multiple sclerosis community. If Lucid-MS proves successful in Phase 2, it could offer a groundbreaking treatment that not only manages symptoms but potentially reverses myelin damage, addressing the root cause of MS. For patients, this could mean a therapy that slows or halts disease progression, improving quality of life. For investors, it represents a significant de-risking of the drug's development, potentially increasing the company's value. The advancement also underscores the growing promise of neuroprotective approaches in treating neurodegenerative diseases.
Summary
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has received FDA clearance to advance its lead drug candidate, Lucid-MS, into Phase 2 clinical trials for multiple sclerosis (MS). The company announced that the U.S. Food and Drug Administration approved its Investigational New Drug (IND) application, allowing the patented, first-in-class therapy to move forward. The upcoming Phase 2 study will be a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy, safety, and tolerability of Lucid-MS in people with MS, using both clinical and radiological measures. Site selection is already underway, with patient enrollment and drug administration expected to begin as soon as possible. This milestone marks a significant step for Quantum BioPharma, which is dedicated to developing innovative treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse.
Lucid-MS is a novel drug candidate that targets protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. Unlike existing MS therapies that primarily modulate the immune system, Lucid-MS is designed to provide neuroprotection by inhibiting demyelination, potentially preventing and even reversing myelin breakdown. In preclinical models, it has demonstrated the ability to halt and reverse the underlying mechanism of MS. The drug also showed a favorable safety profile and was well tolerated in earlier Phase 1 trials in healthy volunteers. Quantum BioPharma reported having more than $10 million in cash, digital assets, and liquid investments as of March 31, 2026, to support the upcoming trials.
Quantum BioPharma, through its wholly owned subsidiary Lucid Psycheceuticals Inc., is focused on the development of Lucid-MS, which is a patented new chemical entity. The company also has other assets, including a stake in Unbuzzd Wellness Inc., from which it receives royalty payments. For more details, visit the full press release at https://ibn.fm/HyWYH. The latest news and updates on QNTM are available at https://ibn.fm/QNTM.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Quantum BioPharma Gets FDA Nod for Lucid-MS Phase 2 MS Trial
